RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $837
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) but lowered the price target from $847 to $837.
November 03, 2023 | 7:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been lowered by RBC Capital from $847 to $837, while maintaining a 'Sector Perform' rating.
The news of RBC Capital lowering the price target for Regeneron Pharmaceuticals could potentially create uncertainty among investors, which might affect the stock's performance in the short term. However, the 'Sector Perform' rating indicates that the stock is expected to perform in line with the sector average, which might balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100